SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$99.04
−0.23%Margins
Gross margin
50.0%
EBITDA margin
-309.5%
EBIT margin
-276.5%
Net margin
-291.6%
FCF margin
-275.5%
-25.1%
Return on equity
-24.0%
Return on assets
-23.8%
Return on invested capital
0.08x
Asset turnover
-$249.3M
Cash from operations
$11
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026